iMDK

iMDK is a small molecule research compound that acts as an inhibitor of the growth factor midkine (MDK) and the PI3K/Akt signaling pathway. It has demonstrated anti-tumor activity in various preclinical models, including non-small cell lung cancer (NSCLC), oral squamous cell carcinoma, and primary effusion lymphoma. The compound induces apoptosis through the activation of the ATF3-CHOP pathway and inhibition of CDK1. Due to its high hydrophobicity and poor water solubility, research has focused on lipid nanoparticle formulations to improve its delivery. Currently, iMDK is utilized primarily as a tool compound in oncology research and is not approved for clinical use in humans.

Other names

3-[2-(4-fluorobenzyl)imidazo[2,1-b][1,3]thiazol-6-yl]-2H-chromen-2-oneCAS 881970-80-5CAS881970-80-5CAS-881970-80-5